Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Endocrinology & Diabetes ResearchISSN: 2470-7570
Masao Hashimoto Author
Subjects of specialization
Affiliation
Department of Internal Medicine, Division of Geriatric Medicine, Nippon Medical School 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Hokkaido University, NIhon University Department of Internal Medicine, Division of Geriatric Medicine, Nippon Medical School 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Biography
Department of Internal Medicine, Division of Geriatric Medicine, Nippon Medical School 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.Hokkaido University, NIhon University Department of Internal Medicine, Division of Geriatric
Publications
Rapid Communication Subscription
The Effect of Colestimide on Visceral Fat Mass and Cytokine Levels in Patients with Metabolic Syndrome
Author(s): Tatsuya Suzuki, Masao Hashimoto, Shoko Futami-Suda, Yoshimasa Igari, Kentaro Watanabe, Hiroshi Nakano, Joan Auwerx, Mitsuhiro Watanabe and Kenzo Oba
The Effect of Colestimide on Visceral Fat Mass and Cytokine Levels in Patients with Metabolic Syndrome
Bile acid–binding resins (BABRs) improve hyperglycemia in patients with type 2 diabetes, and the BABR colesevelam has been approved by the U.S. Food and Drug Administration for use as an antihyperglycemic agent. Colestimide (colestilan) is a new type of anion resin that increases the number of hepatic low-density lipoprotein receptors and decreases serum cholesterol levels by promoting the excretion of bile acids and inhibiting the absorption of cholesterol in the intestine; with these changes, the serum level of low-density lipoprotein cholesterol decreases.
... view more»Social Media
Google Scholars / Researchers Sites
